Catalent, one of the contract manufacturers playing a leading role in coronavirus vaccine production, has struck a deal to offload one of its business units.
This week, the company announced that SK Capital, a major private investment firm focused on the chemicals and pharma industries, has agreed to purchase its blow-fill-seal contract and manufacturing business. The companies did not disclose the financial details of the agreement, but said that they hope to finalize the deal by April.
In a statement, Catalent said that the divestment will allow it to focus on growing its “core activities of developing oral, inhaled and biologic drugs with customers” and rapidly extending its “technological portfolio of new, emerging modalities including cell and gene therapies.”
Once the deal is finalized, the spun-off unit will become a new independent company
Read the press release.
